Health and Healthcare
Biotech Short Interest NOV 2007 II (AMGN, BIIB, CELG, GENZ, GILD, IMCL, MEDX)
Published:
We’ve had a lot of biotech stocks see their shares get the wrath of news over recent days. Now that the November-end NASDAQ Short Interest has been released, we wanted to see how the gains and losses were in short selling activity. Here is the key short selling data on NASDAQ as of November 27, 2007 and Settlement Date of November 30, 2007:
STOCK (Ticker) Shares Short Change
Amgen (AMGN) 29,112,550 +10.89%
Biogen Idec (BIIB) 6,648,180 (9.58%)
Celgene (CELG) 25,751,400 +12.19%
Genzyme (GENZ) 6,536,150 +12.36%
Gilead (GILD) 25,557,168 (1.59%)
Imclone (IMCL) 4,252,342 (13.49%)
Medarex (MEDX) 30,181,760 (7.72%)
As a reminder, Biogen Idec was the one that Wall Street feels is close to being acquired because of its review being announced.
Jon C. Ogg
December 11, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Travel Cards Are Getting Too Good To Ignore
Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.
We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.
It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.
We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
